Ouvrir une session
Nouvelles
MERS Coronavirus: Current Status
28 juillet 2014Une Nouvelle Ère dans le Traitement de l'Infection Chronique par le HCV
08 juin 2011Nouveaux Médicaments Bientôt Disponibles pour l'Infection par le Virus HCV
03 mai 2011Conférences
19th Conference on Retroviruses and Opportunistic Infections (CROI)
XIV International Symposium on Respiratory Viral Infections
Journées Québécoises VIH
Abreviations
Nom | Description |
---|---|
3A IN | Inhibitor of Rhinovirus protein 3A |
a-gluco IN | Alpha-glucosidase I inhibitor |
AASLD | American Association for the Study of Liver Diseases |
ACE | Angiotensin-converting enzyme. |
ACIP | Advisory Committee on Immunization Practices |
ACTG | AIDS Clinical Trials Group |
ADCC | Antibody-dependent cellular cytotoxicity |
ADME | Absorption, distribution, metabolism, excretion |
AE | Adverse event |
AGIN | Anogenital intraepithelial neoplasia |
AK | Adenylate kinase |
ALT | Alanine aminotransferase enzyme (marker of liver injury) |
ANRS | Agence Nationale de Recherche sur le SIDA |
API | Active pharmaceutical ingredient |
Approx. | Approximately |
ARV | Antiretroviral (drug) |
AST | Aspartate aminotransferase enzyme, marker of liver injury |
AVEG | AIDS Vaccine Evaluation Group |
BBB | Blood-brain barrier |
BCG | Bacille Calmette-Guérin (used as vaccine for tuberculosis [TB]) |
BID | Bis in die (twice daily) |
BLA | Biologics License Application |
BPV | Bovine Papillomavirus (member of Papillomaviridae family) |
BVDV | Bovine Viral Diarrhea virus (member of Flaviviridae family) |
CANVAC | Canadian Network for Vaccines and Immunotherapeutics |
CCHFV | Crimean-Congo Haemorrhagic Fever virus (member of Bunyaviridae family) |
CCIC50 | Cell culture inhibitory concentration 50%: concentration of drug inducing 50% cell killing (measure of cytotoxicity) |
CCID50 | Cell culture infective dose 50%: viral dose infecting 50% of cells (better known as TCID50) |
CDC | Centers for Disease Control and Prevention (USA) |
cdk IN | Inhibitor of cellular cyclin-dependent kinase |
cGMP | Current Good Manufacturing Practices |
CHMP | Committee for Human Medicinal Products (EU) |
CIN | Cervical intraepithelial neoplasia |
CMV | Cytomegalovirus (member of Herpesviridae family) |
CNS | Central nervous system |
co-mktg | Co-marketing |
cp | Cold-passaged (viral variant obtained by serial passage at low temperature) |
CPE | Cytopathic effects (in cell culture) |
cpnd | Compound |
CRADA | Cooperative Research and Development Agreement |
CSF | Colony-stimulating factors |
CTA | Clinical Trial Authorization, European equivalent of IND in the US |
CTL | Cytotoxic T-lymphocyte |
Cyclophil IN | Inhibitor of cellular cyclophilin |
DAA | Direct-Acting Antiviral agent |
dCK | Deoxycytidine kinase |
dCK | Deoxycytidine kinase |
ddRNAi | DNA-directed interfering ribonucleic acid |
dGK | Deoxyguanosine kinase |
DHEA | Dehydroepiandrosterone |
DHHS | U.S. Department of Health and Human Services |
DHS IN | Inhibitor of cellular deoxyhypusine synthase |
DKA | Diketo acid |
dL | Deciliter |
DNA | Deoxyribonucleic acid |
DNA Pol IN | DNA polymerase inhibitor |
DOHH IN | Inhibitor of cellular deoxyhypusine hydroxylase |
dsDNA | Double-stranded deoxyribonucleic acid |
DSMB | Data Safety Monitoring Board |
dsRNA | Double-stranded ribonucleic acid |
DTaP | Diphtheria, tetanus, acellular pertussis (vaccine) |
DTH | Delayed-type hypersensitivity |
DTT | Dithiothreitol |
DTwP | Diphtheria, tetanus, whole cells pertussis (vaccine) |
EASL | European Association for the Study of the Liver |
EBV | Epstein-Barr virus (member of Herpesviridae family) |
EC50 | Effective concentration 50% in virus-infected cell culture: concentration of drug which reduces viral replication by 50% |
ECG | Electrocardiogram |
EEE | Eastern Equine Encephalitis virus (member of Togaviridae family) |
EI | Entry inhibitor |
EIF | Elongation initiation factor |
eIPV | Enhanced potency inactivated Poliovirus vaccine |
eiRNA | Expressed interfering ribonucleic acid |
EMEA | European Medicines Evaluation Agency (EU) |
Encaps IN | Encapsidation inhibitor |
env | Retroviral gene encoding envelope glycoproteins |
enz. | Enzyme |
ERIG | Equine anti-Rabies immunoglobulins |
EU | European Union |
EVR | Early virologic response |
Exp. | Expiration |
expr | Expression |
FBS | Fetal bovine serum |
FDA | Food and Drug Administration (USA) |
FFU | Focus-forming units |
fm | Femtomolar (10-15 M) |
g | Gram |
gag | “Group-specific antigen”, retroviral gene encoding core/nucleocapsid structural proteins |
GBV-B | GB virus B, infecting New World monkeys and closely related to HCV (member of Flaviviridae family) |
GI | Gastro-intestinal |
GMP | Guanosine monophosphate |
gp120 | Glycoprotein 120, HIV-specific envelope glycoprotein with molecular weight 120 kD, involved in attachment to cell receptor for viral entry |
GR | Glucocorticoid receptor |
GSH | Glutathione |
GTP | Guanosine triphosphate |
h | Hour |
HA | Hemagglutinin |
HAART | Highly active antiretroviral therapy |
HAI | Inhibition of hemagglutination (assay) |
HAV | Hepatitis A virus (member of Picornaviridae family) |
HBIG | Hepatitis B virus immunoglobulins |
HBV | Hepatitis B virus (member of Hepadnaviridae family) |
HCV | Hepatitis C virus (member of Flaviviridae family) |
HDAC1 IN | Inhibitor of cellular histone deacetylase I enzyme |
HDCV | Human diploid cell vaccine (obtained by propagating virus in cultures of human diploid cells) |
HDV | Hepatitis delta virus (not currently assigned to a viral family) |
HEC | Hydroxyethyl cellulose |
Hel IN | Helicase inhibitor |
Hel-Pri IN | Helicase-primase complex inhibitor |
HEP | High egg passage |
HEV | Hepatitis E virus (not currently assigned to a viral family) |
HHV-1 | Human Herpes virus 1, or Herpes simplex type 1 (HSV-1, Herpesviridae) |
HHV-2 | Human Herpes virus 2, or Herpes simplex type 2 (HSV-2, Herpesviridae) |
HHV-3 | Human Herpes virus 3, or Varicella-Zoster virus (VZV, Herpesviridae) |
HHV-4 | Human Herpes virus 4, or Epstein-Barr virus (EBV, Herpesviridae) |
HHV-5 | Human Herpes virus 5, or human Cytomegalovirus (CMV, Herpesviridae) |
HHV-8 | Human Herpes virus 8, or Kaposi’s Sarcoma Associated Herpesvirus (KSHV, Herpesviridae) |
Hib | Haemophilus influenzae type b |
HIV | Human Immunodeficiency virus (member of Retroviridae family) |
HLA | Human leukocyte antigens |
HPV | Human Papillomavirus (member of Papillomaviridae family) |
HR | Heptad repeat |
HRIG | Human Rabies immunoglobulins |
HRV | Human Rhinovirus (member of Picornaviridae family) |
HSV | Herpes simplex virus (member of Herpesviridae family); HSV-1, Herpes simplex virus type 1; HSV-2, Herpes simplex virus type 2 |
HVTN | HIV Vaccine Trials Network |
IAS-USA | International AIDS Society - USA |
IAVI | International AIDS Vaccine Initiative |
IC50 | Inhibitory concentration 50: concentration of inhibitor needed to achieve 50% inhibition of an enzymatic reaction |
ICAM-1 | Intercellular Adhesion Molecule 1 |
IDE | Investigational Device Exemption (US) |
IFN | Interferon |
Ig | Immunoglobulin |
IgA | Immunoglobulin A |
IgG | Immunoglobulin G |
IgM | Immunoglobulin M |
II | Integrase inhibitor |
IL | Interleukin |
IM | Intramuscular |
IMPDH | Inosine 5’-monophosphate dehydrogenase (needed to assure adequate intracellular pool of guanosine triphosphate) |
IMPDH IN | IMPDH inhibitor |
IND | Investigational New Drug (US) |
Inhib. | Inhibition |
Ion IN | Ion-channel forming protein (viroporin) inhibitor |
IP | Intellectual property |
IPV | Inactivated Poliovirus (or poliomyelitis) vaccine |
IRES | Internal ribosome entry site |
IRES IN | Internal ribosome entry site inhibitor |
ITT | Intent-to-treat |
IV | Intravenous |
JEV | Japanese Encephalitis virus (member of Flaviviridae family) |
kD | Kilodalton (1000 daltons) |
kg | Kilogram |
Ki | Constant of inhibition: measure of enzyme inhibition based on reaction kinetics |
KS | Kaposi’s Sarcoma |
KSHV | Kaposi’s Sarcoma-Associated Herpesvirus (HHV-8, member of Herpesviridae family) |
LCMV | Lymphocytic choriomeningitis virus (member of Arenaviridae family) |
LD50 | Lethal dose 50 (dose associated with 50% mortality in animals) |
LEP | Low egg passage |
LRTI | Lower respiratory tract infection |
M | Molar |
m | Meter |
MAA | Marketing Authorization Application (EU) |
mAb | Monoclonal antibody |
MDR | Multi-drug resistance |
MEP | Multi-Epitope Peptide |
mg | Milligram (10-3 g) |
MHC | Major histocompatibility complex |
MHRA | Medicines and Healthcare products Regulatory Agency (UK) |
MI | Maturation inhibitor |
min. | Minutes |
mktg | Marketing |
mL | Milliliter |
mM | Millimolar (10-3 M) |
mm | Millimeter (10-3m) |
MMR | Measles, Mumps and Rubella combined vaccine |
MOPV | Monovalent oral Poliovirus vaccine |
MPL | Monophosphoryl lipid A, proprietary adjuvant used with certain vaccines |
MPV | Metapneumovirus (member of Paramyxoviridae family) |
mRNA | Messenger ribonucleic acid |
MTP-PE | Muramyl tripeptide (adjuvant) |
MuLV | Murine Leukemia virus (member of Retroviridae family) |
MVA | Modified Vaccinia Ankara (Poxvirus vector obtained by modifying Ankara strain of Vaccinia) |
MW | Molecular weight |
NA | Neuraminidase |
NA IN | Neuraminidase inhibitor |
NBE | New biological entity |
NCE | New chemical entity |
NCI | National Cancer Institute (US) |
NcRTI | Nucleoside-competing reverse transcriptase inhibitor |
NDA | New Drug Application (US) |
NDS | New Drug Submission (Canada) |
NDV | Newcastle Disease virus (member of Paramyxoviridae family) |
NHS | National Health Service (UK) |
NIAID | National Institute of Allergy and Infectious Diseases |
NIBSC | National Institute for Biological Standards and Control (UK) |
NIDDK | National Institute of Diabetes and Digestive and Kidney Diseases |
NIH | National Institutes of Health (US) |
NIID | National Institute of Infectious Diseases (Japan) |
NIMH | National Institute of Mental Health (US) |
NK | Natural killer (cells) |
nM | Nanomolar (10-9 M) |
nm | Nanometer (10-9 m) |
NNRTI | Non-nucleoside reverse transcriptase inhibitor |
NRTI | Nucleoside reverse transcriptase inhibitor |
NS5A IN | Inhibitor of HCV non-structural NS5A phosphoprotein involved in RNA replication complex and pathogenesis |
NSI | Non-syncytium inducing |
OBT | Optimized background therapy |
OD | Orphan Drug (designation or status, US) |
OMP | Orphan Medicinal Product (EU) |
OPV | Oral Poliovirus (or poliomyelitis) vaccine |
ORF | Open reading frame |
OTC | Over-the-counter (drug available without prescription) |
PAHO | Pan-American Health Organization |
PAM | Protease-associated mutations (mutations in viral protease gene associated with resistance to PIs) |
PARP IN | Inhibitor of cellular poly-ADP ribose polymerase |
PATH | Program for Appropriate Technology in Health |
PBMC | Peripheral blood monocyte cells |
PCECV | Primary chick embryo cell vaccine (obtained by propagation of virus in cultures of chicken fibroblasts) |
PCPP | Polyphosphazene (adjuvant for certain vaccines) |
PD | Pharmacodynamics |
PDEV | Purified duck embryo vaccine (obtained by inoculation of virus into embryonated egg, with preparation of vaccine from egg material) |
PED | Pediatric exclusivity |
PEG | Polyethylene glycol |
PEG-IFN | Pegylated interferon |
PEP | Post-exposure prophylaxis |
PFU | Plaque-forming units |
PI | Protease inhibitor |
PIC | Pre-integration complex |
PIC IN | Inhibitor of pre-integration complex |
PIV | Parainfluenza virus (member of Paramyxoviridae family) |
PK | Pharmacokinetics |
pM | Picomolar (10-12 M) |
PML | Progressive multifocal leukoencephalopathy |
PNA | Peptide-nucleic acid |
pol | Retroviral gene encoding reverse transcriptase/RNAseH, protease and integrase enzymes |
PPRTI | Pyrophosphate reverse transcriptase inhibitor |
PR | Protease enzyme |
PRP-T | Polyribosylribitol phosphate (PRP, main component of Haemophilus influenzae outer capsule) conjugated to tetanus toxoid |
pts | Patients |
PVRV | Purified Vero cell Rabies vaccine (obtained by propagation of virus in cultures of Vero cells) |
QD | Once daily |
Regul IN | Inhibitor of viral regulatory protein or gene |
Release IN | Inhibitor of virion release from infected cells |
RIG | Human Rabies immunoglobulins |
RNA | Ribonucleic acid |
RNA Pol IN | RNA polymerase inhibitor |
RNAi | Ribonucleic acid interference |
RNAse | Ribonuclease |
RRP | Recurrent respiratory papillomatosis, caused by some members of Papillomaviridae family |
RSV | Respiratory Syncytial virus (member of Paramyxoviridae family) |
RT | Reverse transcriptase enzyme |
RT-like IN | Inhibitor of reverse transcriptase-like enzyme |
RTI | Reverse transcriptase inhibitor |
RVFV | Rift Valley Fever virus (member of Bunyaviridae family) |
RVR | Rapid virologic response |
SAAVI | South African AIDS Vaccine Initiative |
SAE | Serious adverse event |
SARS | Severe Acute Respiratory Syndrome (caused by member of Coronaviridae family) |
SAVI | SARS Accelerated Vaccine Initiative |
SBIR | Small Business Innovation and Research grant |
sc or SC or SQ | Subcutaneous |
SCID | Severe combined immunodeficiency |
SDF-1 | Stromal cell-derived factor-1 (also called CXCL12), natural ligand for CXCR4 cell co-receptor used by HIV for viral entry |
SI | Syncytium-inducing |
siRNA | Small interfering ribonucleic acid |
SIV | Simian Immunodeficiency virus |
SLEV | St-Louis Encephalitis virus (member of Flaviviridae family) |
SMBV | Suckling mouse brain vaccine (obtained by intracerebral inoculation of virus and preparation of vaccine directly from mouse brain tissue) |
SOC | Standard-of-care |
ssDNA | Single-stranded deoxyribonucleic acid |
SSPE | Subacute sclerosing panencephalitis |
ssRNA | Single-stranded ribonucleic acid |
STD | Sexually transmitted diseases |
STI | Structured (or Strategic) Treatment Interruption |
SV40 | Simian virus 40 (member of Polyomaviridae family) |
SVM | Selective viral mutagenesis |
SVR | Sustained virologic response |
TAM | Thymidine analogue mutations (mutations in HIV reverse transcriptase gene associated with drug resistance, selected for by thymidine analogues azidothymidine and stavudine) |
TAR | Tat-responsive element |
TB | Tuberculosis |
TBEV | Tick-Borne Encephalitis virus (member of Flaviviridae family) |
TCID50 | Tissue culture infective dose 50%: viral dose infecting 50% of cells (sometimes called CCID50) |
Th1 | Cellular arm of immune system |
Th2 | Humoral arm of immune system |
TID | Ter un die (three times per day) |
TK | Thymidine kinase enzyme |
TLR | Toll-like receptor |
TNF | Tumor necrosis factor |
TOPV | Trivalent oral Poliovirus (or poliomyelitis) vaccine |
tRNA | Transfer ribonucleic acid |
ts | Temperature-sensitive |
U | Unit |
UCK-1 | Uridine-cytidine kinase 1 |
UMMS | University of Massachusetts Medical School |
Uncoat IN | Inhibitor of viral uncoating in entry process |
USAFEB | US Armed Forces Epidemiological Board (during World War II) |
USAMRIID | US Army Medical Research Institute of Infectious Diseases |
USAMRMC | US Army Medical Research and Materiel Command |
VAPP | Vaccine-associated paralytic poliomyelitis |
VEE | Venezuelan Equine Encephalitis virus (member of Togaviridae family) |
VIG | Vaccinia immunoglobulins |
VLP | Virus-like particles |
VRC | Vaccine Research Center |
vs | versus |
VSV | Vesicular Stomatitis virus (member of Rhabdoviridae family) |
VZIG | Varicella-Zoster immunoglobulins |
VZV | Varicella-Zoster virus (member of Herpesviridae family) |
WEE | Western Equine Encephalitis virus (member of Togaviridae family) |
WHO | World Health Organization |
WNV | West Nile virus (member of Flaviviridae family) |
WRAIR | Walter Reed Army Institute of Research |
wt or WT | Wild-type |
WWII | World War II |
YFV | Yellow Fever virus (member of Flaviviridae family) |
YMPK | Uridine-cytidine monophosphate kinase (UMP-CMP kinase) |
ZFN | Zinc-finger protein nuclease |
Zn-f IN | Zinc-finger inhibitor |
µg | Microgram (10-6 g) |
µM | Micromolar (10-6 M) |
µm | Micrometer or micron (10-6 m) |